´ëÇÑ°ñ´Ù°øÁõÇÐȸ Ãá°è½ÉÆ÷Áö¾ö ¹× ¿¬¼ö°Á : 2023-04-02±³À°ÀÏÀÚ : 2023-04-02±³À°Àå¼Ò : ´ëÇÑ°ñ´Ù°øÁõÇÐȸ Ãá°è½ÉÆ÷Áö¾ö ¹× ¿¬¼ö°Á °³ÃÖ ±³À°ÁÖÁ¦ : ´ëÇÑ°ñ´Ù°øÁõÇÐȸ Ãá°è½ÉÆ÷Áö¾ö ¹× ¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇÑ°ñ´Ù°øÁõÇÐȸ
´ã´çÀÚ : ¿À¼ºÈñ
¿¬¶ôó : 02-777-9896
À̸ÞÀÏ : work@koreanosteoporosis.or.kr
±³À°Á¾·ù : ³»°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ÀçÈ°ÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаúÀÇ»çÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÁ¤Ã¥, º¸Çè, ±âŸ
Âü¼®¿¹»óÀοø : 350¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ï :
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 09:00~09:20 Current strategies to treat sarcopenia Á¶¹ÎÁØ(¼¿ïÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 09:20~09:40 Basic research in muscle regeneration °ø¿µÀ±(¼¿ï´ë »ý¸í°úÇкÎ)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 09:40~10:00 Muscle regeneration and aging °Á¾¼ø(¼º±Õ°üÀÇ´ë)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 10:00~10:15 Q&A ()
ÈÞ½Ä 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 10:15~10:35 coffee break ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 10:35~10:55 Update on the trabecular bone score in osteoporosis ÃÖ¿ëÁØ(¾ÆÁÖÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 10:55~11:15 Update on the quantitative CT in osteoporosis ±è°æ¹Î(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 11:15~11:35 Accuracy and performances of the 2D to 3D-DXA mapping procedure using 3D-SHAPER¢ç Luca Quagliato(ÀÌÈ¿©´ë ÈÞ¸Õ±â°è¹ÙÀÌ¿À°øÇкÎ)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 11:35~11:50 Q&A ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 11:50~12:10 How to Forging Path Forward for Strengthening Bone Health ±è¼º¼ö(ÀÎÁ¦ÀÇ´ë Á¤Çü¿Ü°ú)
½Ä»ç 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 12:10~13:00 Á¡½É½Ã°£ ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 13:00~13:20 Discontinuing denosumab: Can it be done safely? ±èâÇö(¼øõÇâÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 13:20~13:40 Zoledronate: ´Ù¾çÇÑ ÀÓ»óÀû¿ëÀÇ ½ÇÁ¦ ¹ÚÀç¹Î(¿¬¼¼ÀÇ´ë °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 13:40~14:00 Recent issues for ONJ ¹ÚÁÖ¿µ(¼¿ïÄ¡´ë ±¸°¾Ç¾È¸é¿Ü°ú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 14:00~14:15 Q&A ()
ÈÞ½Ä 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 14:15~14:35 coffee break ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 14:35~14:55 Recent Update on the Safety and Efficacy: Teriparaitde vs. abaloparatide ±è»ó¹Î(°í·ÁÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 14:55~15:15 Modeling Based vs. Remodeling Based Bone Formation: What are the differences? °°æÁß(°æÈñÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 15:15~15:35 Romososumab: ÀÓ»óÀû¿ëÀÇ ½ÇÁ¦ ÀÌȯÈñ(°¡Å縯ÀÇ´ë Á¤Çü¿Ü°ú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 15:35~15:45 Q&A ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 15:45~16:05 Recent Update on the Safety and Efficacy: Teriparaitde vs. abaloparatide ±è»ó¹Î(°í·ÁÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 16:05~16:25 Modeling Based vs. Remodeling Based Bone Formation: What are the differences? °°æÁß(°æÈñÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 16:25~16:45 Romososumab: ÀÓ»óÀû¿ëÀÇ ½ÇÁ¦ ÀÌȯÈñ(°¡Å縯ÀÇ´ë Á¤Çü¿Ü°ú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó1·ë 16:45~16:55 Q&A ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 09:00~09:20 °ñ´ë»ç ±âÃÊ ½±°Ô ÀÌÇØÇϱâ ÃÖÇѼ®(µ¿±¹ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 09:20~09:40 °ñ´Ù°øÁõ Áø´Ü ¹× Æò°¡ÀÇ pitfall ±èöȣ(¿ï»êÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 09:40~10:00 Ç÷¾×°Ë»ç È°¿ë°ú ÃßÀû°üÂû ±æ¶óÀâÀÌ ÇÑ°ÇÈñ(¼¿ïÀÇ·á¿ø °¡Á¤ÀÇÇаú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 10:00~10:15 Q&A ()
ÈÞ½Ä 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 10:15~10:35 Coffee break ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 10:35~10:55 ´Ù¾çÇÑ Ca & Vit. D ¿Ã¹Ù¸£°Ô ¼±ÅÃÇϱ⠱迵»ó(Â÷ÀÇ°úÇÐ´ë °¡Á¤ÀÇÇаú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 10:55~11:15 ³»°úÀû Áúȯ¿¡ µû¸¥ °ñ´Ù°øÁõ ¾àÁ¦¼±Åà ÀÓÁ¤¼ö(¿¬¼¼¿øÁÖÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 11:15~11:35 ±Ù°¨¼ÒÁõ ¹× °ñ´Ù°øÁõ ȯÀÚÀÇ »ýÈ°½À°ü °ü¸® ±è¿ëȯ(ÃæºÏÀÇ´ë °¡Á¤ÀÇÇаú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 11:35~11:50 Q&A ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 11:50~12:10 Expanded Usage of Zoledronic Acid À̵¿¿Á(±¹¸³¾Ï¼¾ÅÍ »êºÎÀΰú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 13:00~13:20 SERM & MHT (Menopausal Hormone Therapy) ±è¼º¿ì(¼¿ïÀÇ´ë »êºÎÀΰú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 13:20~13:40 Bisphosphonate & Denosumab ¾ÈűÙ(Â÷ÀÇ°úÇдë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 13:40~14:00 Romosozumab & Teriparatide ¹ÚÇü¿(°¡Å縯ÀÇ´ë Á¤Çü¿Ü°ú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 14:00~14:15 Q&A ()
ÈÞ½Ä 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 14:15~14:35 Coffee break ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 14:35~14:55 ¹Ýµå½Ã ¾Ë¾Æ¾ß ÇÏ´Â °ñ´Ù°øÁõ º¸Çè±âÁØ ¾÷µ¥ÀÌÆ® À±¼®±â(õ¾È¿£µµ³»°úÀÇ¿ø)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 14:55~15:15 °ñ´Ù°øÁõ Ä¡·á ºñ¹ÝÀÀ±º¿¡ ´ëÇÑ ´ëÀÀ Àü·« ±è±¤ÁØ(¿¬¼¼ÀÇ´ë ³ë³â³»°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 15:15~15:35 °ñ´Ù°øÁõ ¾àÁ¦ º´ÇÕ¿ä¹ý°ú ¼øÂ÷Ä¡·á È«»ó¸ð(ÇѾçÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 15:35~15:45 Q&A ()
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 15:45~16:05 µ¥³ë¼ö¸¿ »ç¿ë½Ã À¯ÀÇÁ¡ ¾÷µ¥ÀÌÆ® ±èÀ¯¹Ì(°¡Å縯°üµ¿ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 16:05~16:25 °ñ´Ù°øÁõ ¾àÁ¦¿Í °ñÀ¯ÇÕ ±è»óÀÏ(°¡Å縯ÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 16:25~16:45 ´ëÇк´¿ø ±¸°¾Ç¾È¸é¿Ü°ú¿¡ ³»¿øÇÑ ONJ ȯÀÚ Ä¡·á °æÇè °øÀ¯ ±èÁØ¿µ(¿¬¼¼Ä¡´ë ±¸°¾Ç¾È¸é¿Ü°ú)
Åä·Ð 04-02 ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÇѶó2·ë 16:45~16:55 Q&A ()